Dose dependency of pharmacokinetics and therapeutic efficacy of pegylated liposomal doxorubicin (DOXIL) in murine models

Journal of Drug Targeting

Volumn 10, Issue 7, 2002, Pages 539-548

  Gabizon, Alberto ^a,b   Tzemach, Dinah ^a   Mak, Lidia ^a   Bronstein, Moshe ^a   Horowitz, Aviva T ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b SHAARE ZEDEK MEDICAL CENTER   (Israel)

Author keywords

Anthracyclines; Chemotherapy; Doxorubicin; Liposomes; Murine; Pharmacokinetics; Reticulo endothelial system; Stealth; Tumors

Indexed keywords

AMMONIUM SULFATE; DOXORUBICIN; LIPOSOME; MACROGOL; PHOSPHOLIPID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; CIRCULATION TIME; COLLOID; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACCUMULATION; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG HALF LIFE; DRUG TISSUE LEVEL; DRUG UPTAKE; ENCAPSULATION; FEMALE; ISOTOPE LABELING; LIVER MICROSOME; MOUSE; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; RETICULOENDOTHELIAL SYSTEM; SHORT SURVEY; SURFACE CHARGE; TUMOR LOCALIZATION;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CHOLESTEROL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG CARRIERS; EXCIPIENTS; FEMALE; HALF-LIFE; LIPOSOMES; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; PHOSPHATIDYLGLYCEROLS; POLYETHYLENE GLYCOLS; TISSUE DISTRIBUTION; TUMOR CELLS, CULTURED;

EID: 0036875746     PISSN: 1061186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/1061186021000072447     Document Type: Short Survey

References (26)

1. Allen, T.M. and Hansen, C. (1991) "Pharmacokinetics of stealth versus conventional liposomes: effect of dose", Biochim. Biophys. Acta 1068, 133-141.
2. Amantea, M.A., Forrest, A., Northfelt, D.W. and Mamelok, R. (1997) "Population pharmacokinetics and pharmacodynamics of pegylated liposomal doxorubicin in patients with AIDS-related Kaposi's sarcoma", Clin. Pharmacol. Ther. 61, 301-311.
3. Cabanes, A., Tzemach, D., Goren, D., Horowitz, A.T. and Gabizon, A. (1998) "Comparative study of the anti-tumor activity of free doxorubicin and Pegylated liposomal doxorubicin in a mouse lymphoma model", Clin. Cancer Res. 4, 499-505.
4. Colbern, G.T., Hiller, A.J., Musterer, R.S., Pegg, E., Henderson, I.C. and Working, P.K. (1999) "Significant increase in antitumor potency of doxorubicin HCI by its encapsulation in pegylated liposomes", J. Liposome Res. 9, 523-538.
5. Daemen, T., Hofstede, G., Ten Kate, M.T., Bakker-Woudenberg, I.A. and Scherphof, G.L. (1995) "Liposomal doxorubicin-induced toxicity: Depletion and impairment of phagocytic activity of liver macrophages", Int. J. Cancer 61, 716-721.
6. Gabizon, A.A. (1995) "Liposome circulation time and tumor targeting: implications for cancer chemotherapy", Adv. Drug Delivery Rev. 16, 285-294.
7. Gabizon, A. (2001) "Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy", Cancer Investig. 19, 424-436.
8. Gabizon, A. and Martin, F. (1997) "Polyethylene-glycol-coated (Pegylated) Liposomal Doxorubicin-Rationale for use in solid tumors", Drugs 54 (Suppl. 4), 15-21.
9. Gabizon, A., Shiota, R. and Papahadjopoulos, D. (1989) "Pharmacokinetics and tissue distribution of doxorubicin encapsulated in stable liposomes with long circulation times", J. Natl Cancer Inst. 81, 1484-1488.
10. Gabizon, A., Chemla, M., Tzemach, D., Horowitz, A.T. and Goren, D. (1996) "Liposome longevity and stability in circulation: effects on the in vivo delivery to tumors and therapeutic efficacy of encapsulated anthracyclines", J. Drug Target. 3, 391-398.
11. Gabizon, A., Goren, D., Horowitz, A.T., Tzemach, D., Lossos, A. and Siegal, T. (1997) "Long-circulating liposomes for drug delivery in cancer therapy: a review of biodistribution studies in tumor-bearing animals", Adv. Drug Delivery Rev. 24, 337-344.
12. Gabizon, A., Goren, D., Cohen, R. and Barenholz, Y. (1998) "Development of liposomal anthracyclines: from basics to clinical applications", J. Control. Release 53, 275-279.
13. Goren, D., Horowitz, A.T., Zalipsky, S., Woodle, M.C., Yarden, Y. and Gabizon, A. (1996) "Targeting of Stealth liposomes to erbB2 (Her/2) receptor: in vitro and in vivo studies", Br. J. Cancer 74, 1749-1756.
14. Haran, G., Cohen, R., Bar, L.K. and Barenholz, Y. (1993) "Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases", Biochim. Biophys. Acta 1151, 201-215.
15. Harrington, K.J., Mohammadtaghi, S., Uster, P.S., Glass, D., Peters, A.M., Vile, R.G. and Stewart, J.S. (2001) "Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled Pegylated liposomes", Clin. Cancer Res. 7, 243-254.
16. Huang, S.K., Lee, K.-D., Hong, K., Friend, D.S. and Papahadjopoulos, D. (1992a) "Microscopic localization of sterically stabilized liposomes in colon carcinoma-bearing mice", Cancer Res. 52, 5135-5143.
17. Huang, S.K., Mayhew, E., Gilani, S., Lasic, D.D., Martin, F.J. and Papahadjopoulos, D. (1992b) "Pharmacokinetics and therapeutics of sterically stabilized liposomes in mice bearing C-26 colon carcinoma", Cancer Res. 52, 6774-6781.
18. Koukourakis, M.I., Koukouraki, S., Giatromanolaki, A., Archimandritis, S.C., Skarlatos, J., Beroukas, K., Bizakis, J.G., Retalis, G., Karkavitsas, N. and Helidonis, E.S. (1999) "Liposomal doxorubicin and conventionally fractionated radiotherapy in the treatment of locally advanced non-small-cell lung cancer and head and neck cancer", J. Clin. Oncol. 17, 3512-3521.
19. Lyass, O., Uziely, B., Ben-Yosef, B., Tzemach, D., Heshing, N.I., Lotem, M., Brufman, G. and Gabizon, A. (2000) "Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast cancer", Cancer 89, 1037-1047.
20. Martin, F.J. (1997) "Pegylated liposomal doxorubicin scientific rationale and preclinical pharmacology", Oncology 11(Suppl. 11), 11-20.
21. Papahadjopoulos, D., Allen, T., Gabizon, A., Mayhew, E., Matthay, K., Huang, S.K., Lee, K.D., Woodle, M.C., Lasic, D.D., Redemann, C. and Martin, F.J. (1991) "Sterically stabilized liposomes: improvements in pharmacokinetics and anti-tumor therapeutic efficacy", Proc. Natl Acad. Sci. USA 88, 11460-11464.
22. Storm, G., Ten Kate, M.T., Working, P.K. and Bakker-Woudenberg, I.A. (1998) "Doxorubicin entrapped in sterically stabilized liposomes: effects on bacterial blood clearance capacity of the mononuclear phagocyte system", Clin. Cancer Res. 4, 111-115.
23. Uziely, B., Jeffers, S., Isacson, R., Kutsch, K., Wei-Tsao, D., Yehoshua, Z., Muggia, F.M. and Gabizon, A. (1995) "Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies", J. Clin. Oncol. 13, 1777-1785.
24. Woodle, M.C. and Lasic, D.D. (1992) "Sterically stabilized liposomes", Biochim. Biophys. Acta 1113, 171-199.
25. Working, P.K. and Dayan, A.D. (1996) "Pharmacological-toxicological expert report. Caelyx (Stealth liposomal doxorubicin HC1)", Hum. Exp. Toxicol. 5, 751-785.
26. Working, P.K., Newman, M.S., Sullivan, T. and Yarrington, J. (1999) "Reduction of the cardiotoxicity of doxorubicin in rabbits and dogs by encapsulation in long-circulating pegylated liposomes", J. Pharmacol. Exp. Ther. 289, 1128-1133.